Roche's Acquisition of Genentech: Retention Program Unlikely to Stem Departures
This article was originally published in Start Up
Executive Summary
Roughly a week after rejecting Roche's initial buy-out proposal, Genentech announced a generous retention plan to employees who commit to staying through June 2009. Trouble is, the retention plan may not offer much incentive, especially to those ineligible for large bonus packages.
You may also be interested in...
Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now
Sanofi-Aventis' much publicized pursuit - first hostile, then friendly - of Genzyme dominated biopharma news flow for more than half a year, with well timed information leaks and dramatic "he said, he said" commentary from the firms' CEOs. Such back and forth ensured continued high profile coverage until the companies officially affianced. But beyond the drama, the $20.1 billion deal, among the largest since the 2009 mega-mergers between Pfizer and Wyeth and Merck & Co. and Schering-Plough Corp., is worth discussion because it provides insight into what now drives big pharma dealmaking in the post-blockbuster era - and how companies want to pay for it.
Astellas Wins OSI But Victory Comes At A Price
Japanese drugmaker Astellas Pharma's painstaking pursuit of OSI Pharmaceuticals is officially over. The victory came at a price, however, costing $4 billion, about $500 million more than Astellas' original hostile bid, launched in late February. That Astellas and OSI managed to find a path forward isn't surprising. Both companies had too much at stake not to see the merger come to fruition.
Astellas Wins OSI But Victory Comes At A Price
Japanese drugmaker Astellas Pharma's painstaking pursuit of OSI Pharmaceuticals is officially over. The victory came at a price, however, costing $4 billion, about $500 million more than Astellas' original hostile bid, launched in late February. That Astellas and OSI managed to find a path forward isn't surprising. Both companies had too much at stake not to see the merger come to fruition.